WO2012134168A2 - Composition for lung cancer treatment and composition for cosmetics containing lysimachiae foenumgraeci herba extract - Google Patents

Abstract

The present invention relates to a novel use of a lysimachiae foenumgraeci herba extract, and more specifically, to a composition for lung cancer treatment and a composition for cosmetics containing, as an active ingredient, a lysimachiae foenumgraeci herba extract having excellent preventative and treatment effects on lung cancer. The lysimachiae foenumgraeci herba extract, according to the present invention, suppresses growth of and induces apoptosis of lung cancer cells, and therefore can be used effectively for lung cancer treatment and prevention.

Description

Composition and cosmetic composition for treating lung cancer comprising Yeongneung extract

The present invention relates to a novel use of Youngneung hyang extract. Specifically, the present invention relates to a therapeutic composition and a cosmetic composition containing Yeongneung-hyang extract as an active ingredient exhibiting excellent prophylactic or therapeutic efficacy against lung cancer.

Among the major diseases of modern people, researches on the treatment and diagnosis of cancer are being conducted mainly on lung cancer, liver cancer, and stomach cancer, which have high incidence. Lung cancer is a malignant tumor in the lung, and it can be divided into primary lung cancer, which is the first cancer cell in bronchial tissue, bronchiole, alveoli, etc. have.

According to the Korea Central Cancer Registry released in 2009, 161,920 cases of cancer occurred in Korea in 2007. Among them, lung cancer was 17,846 cases annually, which ranked 4th with 11.0% of all cancer cases. . The incidence rate per 100,000 population is 36.3. The sex ratio of men and women was 3.51: 1, which was higher in men. The incidence was 12,841 cases per year for men, ranking second among men's cancers, and women's number 5,005 per year, ranking fifth among women's cancers. By age group, 70s accounted for 34.1%, followed by 31.3% in the 60s, and 14.8% in the 50s. (A data released on December 21, 2009, by the Ministry of Health, Welfare and Family Affairs).

Lung cancer is classified microscopically into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) according to the size and shape of the cancer cells. The differentiation between non-small cell lung cancer and small cell lung cancer is due to different clinical course and treatment. Non-small cell lung cancer, which accounts for 80% to 85% of all lung cancers, can be treated by surgical treatment if diagnosed early. Due to the nature of difficult lung cancer, it is often found late and difficult to treat. Non-small cell lung cancer consists of three subtypes: 40% adenocarcinoma, 40% squamous cell carcinoma and 20% large cell carcinoma. TMN staging system is widely accepted for the management of lung cancer. Primary tumors are divided into four T categories (T1-T4) according to tumor size, site and local involvement. Lymph node spread is delivered into the bronchus / pulmonary in the lung (N1), medial spread on the same side as the primary tumor (N2) and mediastinal spread across the primary lung tumor. Or supraclavilcular involvement (N3). There is no distant or metastatic spread (M0 or M1). In general, lung cancer that has not metastasized is treated by surgical removal. However, recurrence rates after lung cancer removal surgery are high (20-50%) (Cancer: Principles & Practice of Oncology, 56th. Ed. In: Devita DV, Hellman S, Rosenberg SA, eds. Philadelphia, PA: Lippincott Williams & Wilkins, 2001 ).

In particular, non-small cell lung cancer has a high recurrence rate after treatment, and compared with a high incidence rate, resistance to conventional chemotherapy with an anticancer agent is easily generated, making it difficult to treat effectively. In the case of the non-small cell lung cancer, the 10-year survival rate is very low, less than 10% despite the recent development of cancer therapy. Therefore, it is very important to develop a treatment for such non-small cell lung cancer.

Yeongneung

Lysimachia foenum-graecum Hance is a biennial herbaceous plant of Primulaceae, its stem is about 70 cm high, its leaves are alternate, and the leaves are double-leaved in summer. It is used when a headache is caused by a cold caused by abundant flowers, and the scent is used to treat bloating symptoms in the abdomen. Originated in Europe, it is also distributed in Korea and is known to have analgesic, anti-inflammatory and whitening effects in oriental medicine.

Lysimachiae Foenumgraeci Herba ( Lysimachia sikokiana Miquel = Lysimachia foenum-graecum Hance) is a perennial herb, whose Latin name is Herba Lysimachiae foenum-Graecumi, which grows in damp areas around the valley and uses it in summer and autumn. . Yeongreunghyang belongs to the Primaceae family and has been traditionally used as herbal medicines such as gamma headache, breast dressing, and roundworm disease. According to the research on the identification of Yeongneung flavor, compounds such as eugenol and methylchavicol have been reported.

However, there is no known effect of Yeongneung-hyang on lung cancer inhibition.

Accordingly, the present inventors completed the present invention by confirming that the extract of Yeongneung-Hyang can effectively kill lung cancer cells during the study of herbal medicine for Yeongneung-Hyang.

It is an object of the present invention to provide a composition for treating lung cancer and a cosmetic composition containing the extract Yeongneung as an active ingredient.

In order to achieve the above object, the present invention provides a composition for the prevention and treatment of lung cancer comprising the active ingredient extracted Yeongneung flavor with an organic solvent. The organic solvent is preferably ethanol.

In another aspect, the present invention provides a cosmetic composition for preventing lung cancer containing the yeongneunghyang ethanol extract containing an cosmetically acceptable cosmetic supplement additive as an active ingredient.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for the prevention and treatment of lung cancer containing Yeongneung ethanol extract as an active ingredient. The composition of the present invention includes Youngneung extract as an active ingredient, and may further include a pharmaceutically acceptable carrier or diluent.

In the composition for preventing and treating lung cancer of the present invention, the ethanol extract is preferably extracted for 24 hours at 50 ℃, wherein the ethanol extract is more preferably dried and concentrated under 45 ℃ reduced pressure conditions, the ethanol is Most preferred is 95%.

In addition, in the composition for preventing and treating lung cancer of the present invention, the lung cancer is preferably non-small cell lung cancer, wherein the non-small cell lung cancer is adenocarcinoma (adenocarcinoma), squamous cell carcinoma (squamous cell carcinoma) and large cell cancer ( More preferably caused by a carcinoma selected from the crowd consisting of large cell carcinoma.

As used herein, the term "lung cancer" refers to a malignant tumor occurring in the lung, and includes both small cell lung cancer and non-small cell lung cancer such as adenocarcinoma, squamous cell carcinoma, and large cell lung cancer.

The "pharmaceutically acceptable carrier" is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.

The composition for treating lung cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient. The carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .

The formulation for pharmacologically extracting Yeongneung extract of the present invention can be administered orally during clinical administration and can be used in the form of general pharmaceutical formulations, and when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrant And diluents such as surfactants or excipients. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and liquid preparations for oral use include suspensions, solvents, emulsions, and syrups. In addition to liquids and paraffins, various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.

In addition, the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set (Uncaria) Uncus, Ponciri Fructus, Ginseng, Gingseng, Liriopis Tuber, Polygalae Radix, Acori graminei Rhizoma, Atractylodis Rhizoma alba, Chrysanthemi Flos, Windproof Radix ), Ginger (Zingiberis Rhizoma crudus), forget-me-not (Natrii sulfas), control (Ziz) yphi Fructus, Salviae Radix, Mautan Radicis Cortex, Rehmanniae Radix, Minthae Herba, Dioscoreae Rhizoma, Polyporus, Polygoni multiflori Radix, Gusi (Allii tube) Semen, Cassiae Semen, Lycii Fructus, Araliae cordatae Radix, Eucommiae Cortex, Hedyotis Herba, Saururus Herba, Artemisiaecapillaris Herba, Anemarrhen Rhizoma, Carthami Flos, Astragali Radix, Lycopodium, Ginkgonis Folium, Polygonati Rhizoma, Nelumbinis Semen, Fossilia ossis Mastodi, Cortexi radics ), Achyranthis Radix, Rehmanniae Radix preparata, Perillae Semen, Thujae Semen, Malt (Hordei Fructus germinatus), Cuscutae Semen, Mordaedae Radix, Sea Song (Pini koraiensis) Radix) and the like can be used alone or in combination.

The composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like. In addition to water, liquid, and paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Specifically, preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used. In addition, calcium or vitamin D ₃ may be added to enhance the efficacy of the treatment. Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as water for injection Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.

The formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination. The invention also includes formulations of dosage units. The formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage. Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times. The individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.

As used herein, the term "extract" refers to an active ingredient isolated from natural products. The extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.

In a specific embodiment of the present invention, Youngneung ethanol extract killed 99.8% of A549 non-small cell lung cancer cells at 100 μg / ml, and EC ₅₀ (half maximal effective concentration) was 9.4 μg / ml. The above results demonstrate that the Youngneung extract of the present invention has excellent killing activity of A549 non-small cell lung cancer cells and further has lung cancer treatment and prophylactic activity.

As used herein, the term "prevention" means any action that inhibits or delays the development of lung cancer by administration of the composition.

As used herein, the term "treatment" means any action that improves or advantageously changes the symptoms of lung cancer by administration of the composition.

Youngneung extract in the present invention can be extracted by using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol. The extracted solution can be used directly or can be concentrated and / or dried. When extracted with an organic solvent, methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized. Depending on the organic solvent to be extracted, the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent. The extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like. Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.

Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration. The drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.

In addition, the extract can perform an additional fractionation process. Preferably, the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.

In the present invention, the term "pharmaceutically acceptable salts" means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases. Examples of suitable acid include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.

The pharmaceutical composition for preventing and treating lung cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition. In addition, the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like. In addition, the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as. In addition, the composition may include a substance having a therapeutic activity against lung cancer, used alone or previously used.

As used herein, the term “patient” refers to humans, horses, sheep, pigs, goats, camels, who have disease caused by lung cancer and its direct and indirect causes, and whose symptoms may be improved by administering the composition of the present invention. Means antelope, dog and other animals. By administering to the patient a composition comprising the extract of Yeongneung for the present invention, it is possible to effectively prevent and treat the above-mentioned lung cancer. The composition of the present invention can be administered in parallel with existing lung cancer therapeutics.

As used herein, the term "administration" means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered. In addition, the composition may be administered by any device in which the active agent may migrate to the target cell.

The composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity. , Drug sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical arts. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art. The method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration. In general, when the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day. Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.

In another aspect, the present invention provides a cosmetic composition for preventing lung cancer containing the yeongneunghyang ethanol extract containing an cosmetically acceptable cosmetic supplement additive as an active ingredient.

The cosmetic composition of the present invention preferably contains 0.01 to 10% by weight, and more preferably 0.1 to 1% by weight, based on the total weight of the ethanol extract. The cosmetic composition of the present invention is not particularly limited in the formulation, for example, it may have a flexible cosmetic water, nourishing cosmetics, massage cream, nutrition cream, pack, gel or skin adhesive type cosmetic formulation, and also lotion, It may be a transdermal dosage form such as an ointment, gel, cream, patch or spray.

In the present invention, when the Youngneung extract of the present invention was injected into A549 non-small cell lung cancer cells, it was confirmed that A549 non-small cell lung cancer cells were killed (see FIG. 1 ). Therefore, it can be seen that the Yeongneung Hyang extract has a therapeutic effect on lung cancer. Thus, in the present invention, the present invention was completed by preparing a cosmetic composition for preventing lung cancer containing Yeongreung extract as an active ingredient (see Preparation Example 2 ).

As discussed above, the Youngneung extract of the present invention inhibits the growth of lung cancer cells and induces apoptosis. Therefore, the composition for treating lung cancer according to the present invention will be very effective in the treatment of lung cancer patients.

1 is a result of Alamar Blue analysis to determine the effect of the introduction of Yeongreung on the growth of lung cancer cells in A549 non-small cell lung cancer cells, which are human lung cancer cells, wherein the X axis is the concentration of the extract of Youngneung, and the Y axis is alive. Survival rate of human lung cancer cells.

Hereinafter, the present invention will be described in more detail based on the following examples. However, the following examples are only for illustrating the present invention, and the present invention is not limited to the following examples and may be changed to other embodiments equivalent to substitutions and equivalents without departing from the technical spirit of the present invention. Will be apparent to those of ordinary skill in the art.

Example 1 Preparation of Youngneung Hyang Extract

3 kg of Yeongneung Hyang (Chinese) purchased from Seoul medicinal herb was dried and ground for 5 days at the shade and room temperature. The ground Yeongneunghyang was soaked in 30 L of 95% ethanol and extracted at 50 ° C. for 24 hours. This was filtered through filter paper, dried and concentrated under reduced pressure at 45 ° C. to obtain 498 g of the total extract, which was stored at −20 ° C.

Example 2 Effect of Youngneung Extract on Growth of Lung Cancer Cells

In order to determine the effect of the Youngneung extract extracted in Example 1 on the growth of lung cancer cells, the A549 non-small cell lung cancer cells, which are human lung cancer cells, were treated with Yeongneung ethanol extract for 48 hours and subjected to Alamar Blue analysis. The Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.

<2-1> Preparation and Treatment of Human Lung Cancer Cell Lines

A549 cells, a lung cancer cell line used in the present invention, were distributed from the Korean Cell Line Bank (KCLB) and used for experiments. Specifically, A549 lung cancer cells RPMI 1640 medium (Robwell Park Memorial) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Subculture was performed in a floating culture medium researched and developed by the Institute.

<2-2> Cell growth inhibition measurement of A549 non-small cell

The Youngneung extract extracted in Example 1 was confirmed to inhibit the growth of lung cancer cells A549 non-small cell growth. Specifically, 1.4 X 10 per each well in a 96 well plate³ Seeds of A549 lung cancer cells in dogs and incubated for 24 hours, then dissolved in DMSO (dimethyl sulfoxide) When the ethanol extract was treated at concentrations of 0 to 100 μg / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50 and 100 μg / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1). After treatment of each concentration of extract, 20 μl of Alamar Blue reagent was added to 0.2 ml of cell culture filled in each well in a 96-well plate, and the plates were incubated for 2 hours in an incubator. The plate was slowly shaken to uniformly react the cells of each well, and the intensity of fluorescence was measured at 590 nm with a fluorescence photometer (Fluorescence Microplate Reader; Molecular Devices Corp.) while irradiating irradiation light at a wavelength of 544 nm. Survival is shown in FIG.

Table 1

Youngneung concentration	Lung Cancer Cell Survival (Average)	Standard Deviation
0 μg / ml	1.000	0.000
3.125 μg / ml	0.710	0.020
6.25 μg / ml	0.654	0.084
12.5 μg / ml	0.588	0.052
25 μg / ml	0.028	0.005
50 μg / ml	0.001	0.001
100 μg / ml	0.002	0.001

As a result, as shown in Table 1 and Figure 1, the higher the treatment concentration of the Yeongneung hyang lung cancer cell growth was reduced, from which it can be seen that Yeongneung hyang has the effect of treating lung cancer. Ie 29.0% at 3.125 μg / ml, 34.6% at 6.25 μg / ml, 41.2% at 12.5 μg / ml, 97.2% at 25 μg / ml, 99.9% at 50 μg / ml, 99.8% at 100 μg / ml Lung cancer cells were killed. In addition, the EC ₅₀ (half maximal effective concentration) was determined to be 9.4 μg / ml. Table 1 describes the relative cell numbers of lung cancer cells after 48 hours according to the concentration of each Yeongneung-based treatment based on the survival rate of lung cancer cells of the control group not treated with Yeongneung-dong. As such, the Youngneung extract of the present invention demonstrates excellent A549 non-small cell lung cancer cell killing activity, and further has lung cancer treatment and prophylactic activity.

Example 3 Acute Toxicity Test by Youngneung Hyang Extract

Youngneung used in the present invention was widely used as a medicinal herb, but it was determined that there is no problem in stability, but the oral administration and intraperitoneal toxicity experiments were performed to confirm this.

Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally at a dose of 5 g / kg in suspension of the Youngneung extract of Example 1 of the present invention in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed, and autopsy was performed to observe abdominal and thoracic organ abnormalities.

As a result, there were no clinical symptoms or deaths in all animals treated with the test substance, and no toxicity change was observed in weight change, blood test, blood biochemical test, autopsy findings, etc. As a result, all of Yeongneung extract did not show toxic changes up to 5 g / kg in rats and the minimum lethal dose (LD ₅₀ ) was determined to be a safe substance of more than 5 g / kg.

Preparation Example 1 Preparation of Lung Cancer Treatments Comprising Yeongneung-hyang Extract as an Active Ingredient

The present inventors have confirmed that the lung cancer treatment effect of the Yeongneung-hyang extract through the above-mentioned excellent to prepare a lung cancer treatment containing the extract as an active ingredient as follows. In addition, the preparation of the following therapeutic agents can be used for the application of not only therapeutic agents but also cosmetic compositions.

<1-1> Soft gelatin capsules (wt%) containing Youngneung extract

Youngneung extract 20%, vitamin C 4.5%, vitamin D ₃ 0.001%, manganese sulfate 0.1%, beeswax 10%, palm oil 25%, safflower seed oil 30.399%

 <1-2> Preparation of Intravenous Formulation Containing Youngnung Hyang Extract (wt%)

Youngneung extract 0.2%, mannitol 0.3%, saline 9.5%

<1-3> Tablet (wt%) containing Youngneung extract

Youngneung extract 35%, vitamin C 10%, vitamin D ₃ 0.001%, manganese sulfate 0.1%, crystalline cellulose 25.0%, lactose 17.999%, magnesium stearate 2%

Preparation Example 2 Preparation of Cosmetic Composition Containing Yeongneung-hyang Extract as an Active Ingredient

The present inventors confirmed that the Yeongneung-hyang extract is excellent in lung cancer treatment activity through the above embodiment to prepare a cosmetic composition containing it as an active ingredient as follows.

<2-1> Nutritional Cosmetic Water Containing Youngneung Hyang Extract (wt%)

Nutrients were prepared in a conventional manner according to the composition described below.

Glycerin 8.0%, Butylene Glycol 4.0%, Hyaluronic Acid Extract 5.0%, Betaglucan 7.0%, Carbomer 0.1%, Youngneung Extract 0.05%, Capric / Capric Triglyceride 8.0%, Squalane 5.0%, Cetearyl Glucoside 1.5%, sorbitan stearate 0.4%, cetearyl alcohol 1.0%, triethanol amine 0.1%, remaining amount of purified water

<2-2> Nutritional Cream Containing Youngneung Hyang Extract (% by weight)

The nourishing cream was prepared by a conventional method according to the composition described below.

Glycerin 3.0%, Butylene Glycol 3.0%, Liquid Paraffin 7.0%, Beta Glucan 7.0%, Carbomer 0.1%, Youngneung Extract 3.0%, Capilic / Capric Triglyceride 3.0%, Squalane 5.0%, Cetearyl Glucoside 1.5 %, Sorbitan stearate 0.4%, polysorbate 60 1.2%, triethanol amine 0.1%, purified water balance

<2-3> Massage cream containing Youngneung extract (wt%)

Massage creams were prepared in a conventional manner according to the composition described below.

Glycerin 8.0%, Butylene Glycol 4.0%, Liquid Paraffin 45.0%, Beta Glucan 7.0%, Carbomer 0.1%, Youngneung Extract 1.0%, Capphilic / Capric Triglyceride 3.0%, Beeswax 4.0%, Cetearyl Glucoside 1.5 %, Sesqui oleic acid sorbitan 0.9%, petrolatum 3.0%, paraffin 1.5%, remaining amount of purified water

<2-4> Pack containing weight extract of Youngneung

Packs were prepared by conventional methods according to the compositions described below.

Glycerin 4.0%, Polyvinyl Alcohol 15.0%, Hyaluronic Acid Extract 5.0%, Betaglucan 7.0%, Allantoin 0.1%, Youngneung Extract 0.5%, Nonyl Phenylether 0.4%, Polysorbate 60 1.2%, Ethanol 6.0%, Purified Water Residue

<2-5> Ointment for external application of skin containing Yeongneung flavor extract (% by weight)

Ointments were prepared in a conventional manner according to the compositions described below.

Glycerin 8.0%, Butylene Glycol 4.0%, Liquid Paraffin 15.0%, Betaglucan 7.0%, Carbomer 0.1%, Youngneung Extract 3.0%, Squalane 1.0%, Cetearyl Glucoside 1.5%, Sorbitan Stearate 0.4%, Three Tearyl alcohol 1.0%, beeswax 4.0%, purified water balance

On the other hand, the specific scope of the present invention is defined by the claims rather than the embodiments described above, all changes and modifications derived from the meaning and scope and equivalent concepts of the claims to the scope of the invention It should be interpreted as including.

Claims (8)

1. Lung cancer prevention and treatment composition comprising the active ingredient extracted Yeongneung flavor with an organic solvent.
2. The composition for preventing and treating lung cancer according to claim 1, wherein the organic solvent is ethanol.
3. The composition for preventing and treating lung cancer according to claim 2, wherein the active ingredient extracted with ethanol is extracted for 24 hours at 50 ° C.
4. According to claim 3, wherein the ethanol extract is lung cancer prevention and treatment composition, characterized in that the dried and concentrated under reduced pressure conditions 45 ℃.
5. The composition for preventing and treating lung cancer according to any one of claims 1 to 4, wherein the composition comprises a pharmaceutically acceptable carrier or diluent.
6. The composition for preventing and treating lung cancer according to any one of claims 1 to 4, wherein the lung cancer is non-small cell lung cancer.
7. The method of claim 6, wherein the non-small cell lung cancer is caused by a carcinoma selected from the group consisting of adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. And therapeutic compositions.
8. A cosmetic composition for preventing lung cancer containing Yeongneung-hyang ethanol extract containing cosmetically acceptable cosmetic auxiliary additives as an active ingredient.

Images